Benzinga

Benzinga

Benzinga

martes, septiembre 01

Orchestra BioMed Holdings Inc

OBIONASDAQ
Trade with Public
Trade with Public
$5.04
-0.14-2.8%
al cierre: Aug 31, 5:00 PM EST
$5.11
0.07181.42%
After hour: 7:02 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Orchestra BioMed Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Orchestra BioMed Hldgs (OBIO).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$13Upside to Avg. PT+157.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026Piper SandlerMatt O'BrienPT RaiseOverweight$9→$10
May 19, 2026B. Riley SecuritiesKyle BauserPT CutBuy$12→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10

B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13

Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.
Benzinga Newsdesk

Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts

Benzinga Insights

PRO
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12

Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $11 to $12.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved